Publications by authors named "Yanina F Kutasevych"

2 Publications

  • Page 1 of 1

Effectiveness of psychopharmacotherapy in psoriasis patients with associated anxiety and depression.

Dermatol Ther 2020 11 20;33(6):e14292. Epub 2020 Sep 20.

Central Michigan University, College of Medicine, Saginaw, Michigan, USA.

Psoriasis is associated with psychological comorbidities. We evaluated the effectiveness of additional psychopharmacotherapy on the clinical severity and associated anxiety and depression in psoriasis. 173 patients were enrolled with psoriasis and associated anxiety and depression. Spielberger State-Trait Anxiety Inventory (STAI) and The Beck Depression Scale (BDI) were used to assess anxiety and depression parameters. The IA main group included patients with anxiety disorders who received Mebicar. The IB main group consisted of patients with anxiety and depressive disorders who received Mianserin. The II group comprised patients with anxiety disorders (IIA comparison group) and patients with anxiety and depressive disorders (IIB comparison group), who received only traditional therapy. The level of anxiety in patients of the IA and IB main groups decreased by 2.1 times. The level of depression in the IB main group significantly decreased by 1.7 times, while in the IIB comparison group, this indicator remained almost at the same level. Patients of the IA and IB main groups had PASI50 on average on 15 to 16 days of treatment. PASI50 was achieved in the both comparison groups only at 21 to 22 days. PASI75 occurred in the IA and IIB main groups almost simultaneously on 28 to 29 days of treatment. But in the IIA and IIB comparison groups, these positive changes occurred significantly later than in patients of the main groups (on 34-35 days of treatment). Additional psychopharmacotherapy significantly reduced anxiety and depression in both groups IA and IB, as compared to patients in groups IIA and IIB who received only traditional therapy.
View Article and Find Full Text PDF

Download full-text PDF

Source Listing
November 2020

Disorders of the skin's barrier function in patients with atopic dermatitis with mutations of the filaggrin gene.

Wiad Lek 2019 ;72(12 cz 1):2293-2299

SE «Institute of Dermatology and Venereology of Nams of Ukraine», Kharkiv, Ukraine.

Objective: Introduction: The paper presents the results of investigations of the skin's barrier function in patients diagnosed with atopic dermatitis (AD) with the presence of one of the genetic predispositions, namely the filaggrin gene FLG 2284del4 mutation. The aim: to deepen the study of the relationship between the mutations of the gene FLG del2282 and the morphological features of the skin, since the data on its physiological state in patients diagnosed with AD are contradictory that will contribute to the improvement of the modern basis necessary for the development of treatment-diagnostic and preventive measures.

Patients And Methods: Materials and methods: In the given study of patients diagnosed with AD (41 person), the frequency of the FLG 2282del4 gene deletion constituted 19.51% (8 patients) according to the method of Palmer et al. To determine the functional parameters of the skin in patients diagnosed with AD in the carriers of the FLG gene mutation and in patients void of this mutation, they have applied a multifunctional Aramo TS portable analyzer that enables to carry out dermatoscopic diagnosis of the skin surface.

Results: Results and conclusions: As a result of the analysis of the obtained physiological parameters of the skin in the patients of both groups during the treatment process, it is noteworthy that the dynamics of these indices after treatment in patients void of the filaggrin gene mutation is significantly better in comparison with the patients in whom the filaggrin 2282 del14 gene mutation was revealed. There is a tendency towards the decrease of skin's moisture and elasticity in patients with revealed mutation compared with the ones who are void of it. Given this fact, the study of physiological parameters of the skin is important to consider when substantiating the diagnostic-treatment and prophylactic algorithm for patients diagnosed with AD.
View Article and Find Full Text PDF

Download full-text PDF

March 2020